Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma

Abstract

Use of NAC has increased significantly over time to a modest rate of 32%. However, disparities still exist in the receipt of NAC, and future efforts aimed at mitigating these disparities are warranted.